James Dahlman
PhD
Dr. Dahlman is a chemical and bioengineer whose work lies at the interface of nanotechnology, genomics, and gene editing.
Titles and Roles
- Associate Professor, McCamish Foundation Early Career Professorship, Department of Biomedical Engineering
- Georgia Institute of Technology
- Research Program
- Discovery and Developmental Therapeutics
Biography
James Dahlman, PhD, is Associate Professor and holds the McCamish Foundation Early Career Professorship in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech University. Dr. Dahlman is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute.
Education
Dr. Dahlman received his PhD from MIT and Harvard Medical School in 2014, where he studied RNA delivery with Robert Langer and Daniel Anderson. He studied RNA design and gene editing as a post-doc with Feng Zhang at the Broad Institute.
Research
Dr. Dahlman is interested in drug delivery, targeted in vivo gene editing, and using genomics to improve biomaterial design. He has designed and synthesized nanoparticles that efficiently deliver RNAs to the lung and heart. These nanoparticles can deliver multiple RNAs at once, and can simultaneously knockdown five genes concurrently in vivo. They have been used by over ten labs across the United States to study cancer, atherosclerosis, inflammation, emphysema, and pulmonary hypertension, and are being evaluated for clinical trials.
Publications
Publications Publication Date